-
Talk to Us: info@nidccglobal.org
-
Location: Washington, DC | Abuja, Nigeria
Language:
Everyday Economic News
Salesforce (CRM) to Acquire Metering Platform M3ter to Enhance Agentforce Revenue Management
Salesforce (NYSE: CRM) is set to acquire m3ter, a metering and rating platform, to integrate its consumption-based monetization capabilities into Salesforce's Agentforce Revenue Management system. This acquisition aims to equip enterprises with tools for implementing and billing flexible, usage-based pricing models, particularly relevant for the AI era. The transaction is expected to close in Q2 of Salesforce's fiscal year 2027, allowing Salesforce to scale advanced billing capabilities across its global customer base and facilitate a shift toward AI-driven pricing.
Salesforce (CRM) to Acquire Metering Platform M3ter to Enhance Agentforce Revenue Management
Salesforce Inc. (CRM) has signed an agreement to acquire m3ter, a metering and rating platform specializing in consumption-based monetization. This acquisition aims to integrate m3ter’s capabilities into Salesforce's Agentforce Revenue Management system, allowing enterprises to implement and bill for flexible, usage-based pricing models essential for the AI era. The transaction is expected to close in Q2 of Salesforce’s fiscal year 2027 and will enable the company to scale advanced billing capabilities across its global customer base.
FinancialContent - Murchinson Invites Fellow Nano Dimension Shareholders to Participate In a Survey: What Trendy Industry Is the Board, Under Chairman Bob Pons' Leadership, Planning to Chase Next?
Murchinson Ltd., a significant shareholder of Nano Dimension (NASDAQ: NNDM), has issued a letter to fellow shareholders expressing concern over the Board's evaluation of "exciting opportunities" under Chairman Robert Pons. Murchinson suggests these potential transactions might be self-serving and value-destructive, similar to past leadership actions. The firm is inviting shareholders to participate in a survey to predict which trendy industry the Board might pursue next and what remuneration Messrs. Pons and Stehlin might receive.
Rupert Resources Obtains Final Court Approval and Announces Expected Closing Date for Arrangement With Agnico Eagle
Rupert Resources Ltd. has received final court approval for its arrangement with Agnico Eagle Mines Limited, where Agnico Eagle will acquire all outstanding common shares of Rupert Resources it does not already own. Each share will be exchanged for 0.0401 of an Agnico Eagle common share and a contingent value right up to C$3.00, payable upon certain milestones. The companies anticipate the arrangement to close on or about June 16, 2026.
Adial Pharmaceuticals (ADIL) Acquires Azora Therapeutics and Secures $64M Financing
Adial Pharmaceuticals (ADIL) has acquired Azora Therapeutics, gaining the lead asset AT177 for inflammatory diseases. The acquisition is backed by a $64 million private placement, with $32 million immediately available and the remainder contingent on Phase 1 trial initiation for AT177 in ulcerative colitis. The company also appointed Wendy Young, Ph.D., to its Board of Directors, as it navigates a critical development phase despite a low GF Score™ indicating profitability challenges.
5 Best Canadian Infrastructure Stocks to Buy Now
TransAlta Corporation (NYSE:TAC) has entered an agreement to acquire Mountain Peak Power and Canyon Peak Power, two natural gas peaking facilities near Denver, Colorado, for $1 billion. The acquisition, expected to close in early Q4 2026, will add a combined 318 MW capacity and about $80M of adjusted EBITDA annually. Despite recent price target reductions from BMO Capital and TD Securities, both firms maintained Outperform and Buy ratings, respectively, on TransAlta shares.
Adial Pharmaceuticals Announces Acquisition Of Azora Therapeutics And Up To $64 Million Financing
Adial Pharmaceuticals has announced the acquisition of Azora Therapeutics, along with securing financing of up to $64 million. This strategic move is expected to bolster Adial Pharmaceuticals' operations and therapeutic development pipeline.
Humana to sell off minority stake in end-of-life care provider Gentiva
Humana announced its intention to divest its minority stake in Gentiva, the largest provider of end-of-life care in the U.S. The agreement values Humana's stake at approximately $900 million, and the deal is expected to close in Q3 2026, pending regulatory approval. Humana plans to use the proceeds for general corporate purposes, not anticipating a material impact on its earnings for the year.